Jounce Therapeutics Inc (JNCE)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Richard Murray
Employees:
140
780 MEMORIAL DRIVE, CAMBRIDGE, MA 02139
857-259-3840

Jounce Therapeutics, Inc. develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2.

Data derived from most recent annual or quarterly report
Market Cap 98.024 Million Shares Outstanding52.14 Million Avg 30-day Volume 1.538 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.99
Price to Revenue0.6995 Debt to Equity0.0 EBITDA-47.794 Million
Price to Book Value0.3133 Operating Margin-63.70980000000001 Enterprise Value-132.182 Million
Current Ratio8.369 EPS Growth0.456 Quick Ratio8.042
1 Yr BETA 0.728 52-week High/Low 5.87 / 0.58 Profit Margin-62.0963
Operating Cash Flow Growth65.4143 Altman Z-Score-0.1816 Free Cash Flow to Firm -26.557 Million
View SEC Filings from JNCE instead.

View recent insider trading info

Jounce Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding JNCE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding JNCE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-05-05 by CONCENTRA BIOSCIENCES, LLC
  • 4: filed on 2023-05-05 by TANG KEVIN C
  • 3: filed on 2023-05-05 by CONCENTRA BIOSCIENCES, LLC
  • 4: filed on 2023-05-04 by SALTER-CID LUISA
  • 4: filed on 2023-05-04 by RAYTHATHA JIGAR
  • 4: filed on 2023-05-04 by MURRAY RICHARD
  • 4: filed on 2023-05-04 by KARSEN PERRY A
  • 4: filed on 2023-05-04 by KAMEN ROBERT
  • 4: filed on 2023-05-04 by IANNONE ROBERT
  • 4: filed on 2023-05-04 by DUNCAN BARBARA GAYLE

    • Events (8k)

  • 8-K: filed on 2023-05-04:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-03-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-15:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 3.02: Unregistered Sales of Equity Securities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-05:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-12-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    • Proposed Sales (Form 144)

  • 144: filed on 2023-01-09:
  • 144: filed on 2023-01-09:
  • 144: filed on 2023-01-09:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    39.2 Thousand total shares from 1 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    TANG KEVIN C

    TANG CAPITAL MANAGEMENT LLC

    TANG CAPITAL PARTNERS LP

    • Director
    • 10% Owner
    		 10,000 2023-05-03 3

    MURRAY RICHARD /CA/

    • Director
    		 1 2023-05-03 3

    KARSEN PERRY A

    • Director
    		 0 2023-05-03 2

    DRAPKIN KIMBERLEE C PRESIDENT, CFO AND TREASURER

    • Officer
    		 0 2023-05-03 2

    DUNCAN BARBARA GAYLE

    • Director
    		 0 2023-05-03 2

    KAMEN ROBERT

    • Director
    		 0 2023-05-03 2

    DIAZ LUIS

    • Director
    		 0 2023-05-03 2

    IANNONE ROBERT

    • Director
    		 0 2023-05-03 2

    RAYTHATHA JIGAR

    • Director
    		 0 2023-05-03 2

    SALTER-CID LUISA

    • Director
    		 0 2023-05-03 2

    CONCENTRA BIOSCIENCES, LLC

    • 10% Owner
    		 10,000 2023-05-03 2

    CONCENTRA BIOSCIENCES, LLC

    CONCENTRA MERGER SUB, INC.

    • 10% Owner
    		 36,367,727 2023-05-03 2

    COLE HUGH M CHIEF OPERATING OFFICER

    • Officer
    		 110,082 2023-01-09 2

    TREHU ELIZABETH CHIEF MEDICAL OFFICER

    • Officer
    		 103,417 2023-01-09 1

    HIGGONS JOHN DUNCAN

    • Director
    		 20,000 2022-06-24 1

    THIRD ROCK VENTURES III, L.P.

    THIRD ROCK VENTURES GP III, L.P.

    TRV GP III, LLC

    STARR KEVIN P

    TEPPER ROBERT I

    LEVIN MARK J

    • 10% Owner
    		 4,698,661 2021-11-12 0

    PFEFFER CARY

    • Director
    		 50,468 2021-11-12 0

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    STARR KEVIN P

    TEPPER ROBERT I

    LEVIN MARK J

    • 10% Owner
    		 6,598,661 2021-09-15 0

    GILEAD SCIENCES INC

    • 10% Owner
    		 5,539,727 2020-10-16 0

    TEPPER ROBERT I

    • Director
    • 10% Owner
    		 0 2020-06-26 0

    CELGENE SWITZERLAND LLC

    CELGENE CORP /DE/

    • 10% Owner
    		 3,456,463 2017-02-01 0

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    THIRD ROCK VENTURES III, L.P.

    THIRD ROCK VENTURES GP III, L.P.

    TRV GP III, LLC

    LEVIN MARK J

    STARR KEVIN P

    • 10% Owner
    		 3,048,780 2017-02-01 0

    HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.

    • 10% Owner
    		 No longer subject to file 2017-02-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    KAMEN ROBERT - Director

    		2023-05-04 07:44:21 -0400 2023-05-03 D 15,700 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 175,000 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 182,926 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 U 188,778 d 1 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 200,000 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 665,169 d 0 direct

    KARSEN PERRY A - Director

    		2023-05-04 07:44:37 -0400 2023-05-03 U 5,000 d 0 direct

    KARSEN PERRY A - Director

    		2023-05-04 07:44:37 -0400 2023-05-03 D 13,350 d 0 direct

    KARSEN PERRY A - Director

    		2023-05-04 07:44:37 -0400 2023-05-03 D 15,700 d 0 direct

    KARSEN PERRY A - Director

    		2023-05-04 07:44:37 -0400 2023-05-03 D 15,700 d 0 direct

    KARSEN PERRY A - Director

    		2023-05-04 07:44:37 -0400 2023-05-03 D 15,700 d 0 direct

    KARSEN PERRY A - Director

    		2023-05-04 07:44:37 -0400 2023-05-03 D 16,260 d 0 direct

    KARSEN PERRY A - Director

    		2023-05-04 07:44:37 -0400 2023-05-03 D 20,000 d 0 direct

    KARSEN PERRY A - Director

    		2023-05-04 07:44:37 -0400 2023-05-03 D 75,880 d 0 direct

    KAMEN ROBERT - Director

    		2023-05-04 07:44:21 -0400 2023-05-03 D 10,840 d 0 direct

    KAMEN ROBERT - Director

    		2023-05-04 07:44:21 -0400 2023-05-03 D 13,550 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 165,954 d 0 direct

    KAMEN ROBERT - Director

    		2023-05-04 07:44:21 -0400 2023-05-03 D 15,700 d 0 direct

    KAMEN ROBERT - Director

    		2023-05-04 07:44:21 -0400 2023-05-03 D 15,700 d 0 direct

    KAMEN ROBERT - Director

    		2023-05-04 07:44:21 -0400 2023-05-03 D 20,000 d 0 direct

    KAMEN ROBERT - Director see footnote

    		2023-05-04 07:44:21 -0400 2023-05-03 U 33,875 d 0 indirect

    KAMEN ROBERT - Director

    		2023-05-04 07:44:21 -0400 2023-05-03 U 60,975 d 0 direct

    IANNONE ROBERT - Director

    		2023-05-04 07:43:59 -0400 2023-05-03 D 7,850 d 0 direct

    IANNONE ROBERT - Director

    		2023-05-04 07:43:59 -0400 2023-05-03 D 15,700 d 0 direct

    IANNONE ROBERT - Director

    		2023-05-04 07:43:59 -0400 2023-05-03 D 20,000 d 0 direct

    IANNONE ROBERT - Director

    		2023-05-04 07:43:59 -0400 2023-05-03 D 31,400 d 0 direct

    SALTER-CID LUISA - Director

    		2023-05-04 07:45:31 -0400 2023-05-03 D 7,850 d 0 direct

    SALTER-CID LUISA - Director

    		2023-05-04 07:45:31 -0400 2023-05-03 D 20,000 d 0 direct

    SALTER-CID LUISA - Director

    		2023-05-04 07:45:31 -0400 2023-05-03 D 31,400 d 0 direct

    CONCENTRA BIOSCIENCES, LLC - > 10% Owner

    		2023-05-05 16:38:21 -0400 2023-05-03 J 10,000 $9,737.70 a 10,000 direct

    TANG KEVIN C - Director - > 10% Owner by lp

    TANG CAPITAL MANAGEMENT LLC - > 10% Owner by lp

    TANG CAPITAL PARTNERS LP - > 10% Owner by lp

    		2023-05-05 16:37:26 -0400 2023-05-03 J 10,000 $9,737.70 a 10,000 indirect

    TANG KEVIN C - Director - > 10% Owner by lp

    TANG CAPITAL MANAGEMENT LLC - > 10% Owner by lp

    TANG CAPITAL PARTNERS LP - > 10% Owner by lp

    		2023-05-05 16:37:26 -0400 2023-05-03 U 5,300,087 $1.85 d 0 indirect

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 D 97,500 d 0 direct

    DUNCAN BARBARA GAYLE - Director

    		2023-05-04 07:43:41 -0400 2023-05-03 D 10,840 d 0 direct

    DUNCAN BARBARA GAYLE - Director

    		2023-05-04 07:43:41 -0400 2023-05-03 D 13,550 d 0 direct

    DUNCAN BARBARA GAYLE - Director

    		2023-05-04 07:43:41 -0400 2023-05-03 D 15,700 d 0 direct

    DUNCAN BARBARA GAYLE - Director

    		2023-05-04 07:43:41 -0400 2023-05-03 D 15,700 d 0 direct

    DUNCAN BARBARA GAYLE - Director

    		2023-05-04 07:43:41 -0400 2023-05-03 D 15,700 d 0 direct

    DUNCAN BARBARA GAYLE - Director

    		2023-05-04 07:43:41 -0400 2023-05-03 D 20,000 d 0 direct

    DUNCAN BARBARA GAYLE - Director

    		2023-05-04 07:43:41 -0400 2023-05-03 D 34,271 d 0 direct

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 D 8,130 d 0 direct

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 U 25,751 d 40,267 direct

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 U 40,267 d 0 direct

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 D 44,500 d 0 direct

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 D 44,500 d 0 direct

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 D 53,400 d 0 direct

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 D 55,000 d 0 direct

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 D 77,235 d 0 direct

    DRAPKIN KIMBERLEE C - Officer PRESIDENT, CFO AND TREASURER

    		2023-05-04 07:43:24 -0400 2023-05-03 D 206,005 d 0 direct

    DIAZ LUIS - Director

    		2023-05-04 07:43:08 -0400 2023-05-03 D 10,163 d 0 direct

    DIAZ LUIS - Director

    		2023-05-04 07:43:08 -0400 2023-05-03 D 15,700 d 0 direct

    DIAZ LUIS - Director

    		2023-05-04 07:43:08 -0400 2023-05-03 D 15,700 d 0 direct

    DIAZ LUIS - Director

    		2023-05-04 07:43:08 -0400 2023-05-03 D 15,700 d 0 direct

    DIAZ LUIS - Director

    		2023-05-04 07:43:08 -0400 2023-05-03 D 20,000 d 0 direct

    DIAZ LUIS - Director

    		2023-05-04 07:43:08 -0400 2023-05-03 D 27,100 d 0 direct

    RAYTHATHA JIGAR - Director

    		2023-05-04 07:45:13 -0400 2023-05-03 D 20,000 d 0 direct

    RAYTHATHA JIGAR - Director

    		2023-05-04 07:45:13 -0400 2023-05-03 D 31,400 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 15,000 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 54,200 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 125,010 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 150,000 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-05-04 07:44:53 -0400 2023-05-03 D 150,010 d 0 direct

    MURRAY RICHARD /CA/ - Director

    		2023-04-06 16:37:50 -0400 2023-04-04 S 39,228 $1.85 d 188,779 direct yes 0.0 2.6738 2.6738 4 0.0 1

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 22:15:04 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 21:45:04 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 21:15:04 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 20:45:04 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 20:15:04 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 19:45:04 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 19:15:04 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 18:45:03 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 18:15:04 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 17:45:03 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 17:15:04 UTC 3.4156 1.4044 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 16:45:04 UTC 3.3042 1.5158 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 16:15:04 UTC 3.3042 1.5158 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 15:45:04 UTC 3.3042 1.5158 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 15:15:03 UTC 3.3042 1.5158 15000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 14:45:03 UTC 3.3042 1.5158 10000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 14:15:04 UTC 3.3042 1.5158 10000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 13:45:04 UTC 2.9642 1.8558 10000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 13:15:04 UTC 2.9642 1.8558 10000
    JOUNCE THERAPEUTICS INC JNCE 2023-05-04 12:45:04 UTC 2.9642 1.8558 10000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments